Biotech Consolidation: Even News is No News
Executive Summary
The only thing more noteworthy about the recent biotech M&A is than its volume is the silence that surrounds it: from Wall Street, the press, and Big Pharma. The problem is the consolidations themselves: largely intra-biotech affairs. Unless Big Pharma gets involved--and they've shown no interest in doing so--investors aren't going to get paid in what they want most out of an acquisition: liquid currency.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.